Innovative Treatment Using Preserved Acellular Descemet Membrane for Refractory Macular Hole

Innovative Treatment Study Using Preserved Acellular Descemet Membrane in Refractory Macular Hole Surgery - PADM for Macular Hole Surgery

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056826

Enrollment

Registered

2025-01-27

Start date

2025-01-06

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory macular hole

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have undergone vitrectomy with Descemet membrane transplantation for refractory macular holes at Yokohama Minami Kyosai Hospital, Nihon University Itabashi Hospital, Yokohama City University Hospital, or Kikuna Yuda Eye Clinic, and for whom informed consent has been obtained.

Exclusion criteria

Exclusion criteria: Patients with poor compliance to follow-up or those unable to tolerate surgery due to systemic disease or severe ocular inflammation are excluded.

Design outcomes

Primary

Measure	Time frame
The presence or absence of macular hole closure, as evaluated by optical coherence tomography (OCT), during a postoperative period (e.g., at the time of intraocular gas absorption, 1 month postoperatively, 3 months postoperatively, or 6 months postoperatively).	—

Secondary

Measure	Time frame
During the postoperative period (e.g., at the time of intraocular gas absorption, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, etc.), best-corrected visual acuity (BCVA; measured using a standard logarithmic visual acuity chart and converted to logMAR), macular sensitivity (evaluated based on thresholds measured using static perimetry and Micro Perimeter 3), changes in intraocular pressure (IOP), and macular structure analyzed using optical coherence tomography (OCT), among others.	—

Measure

Time frame

During the postoperative period (e.g., at the time of intraocular gas absorption, 1 month postoperatively, 3 months postoperatively, 6 months postoperatively, etc.), best-corrected visual acuity (BCVA; measured using a standard logarithmic visual acuity chart and converted to logMAR), macular sensitivity (evaluated based on thresholds measured using static perimetry and Micro Perimeter 3), changes in intraocular pressure (IOP), and macular structure analyzed using optical coherence tomography (OCT), among others.

—

Countries

Japan

Contacts

Public ContactYuki Mizuki

Yokohama Minami Kyosai Hospital Department of Ophthalmology

mizuki.yuk.xj@yokohama-cu.ac.jp0457822101

Outcome results